EPS for Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Expected At $-1.33

January 13, 2018 - By Marguerite Chambers

 EPS for Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Expected At $ 1.33

Analysts expect Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) to report $-1.33 EPS on February, 13.After having $-1.19 EPS previously, Biohaven Pharmaceutical Holding Company Ltd.’s analysts see 11.76 % EPS growth. The stock increased 1.19% or $0.31 during the last trading session, reaching $26.44. About 195,387 shares traded. Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) has 0.00% since January 13, 2017 and is . It has underperformed by 16.70% the S&P500.

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) Ratings Coverage

Among 2 analysts covering Biohaven Pharmaceutical (NYSE:BHVN), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Biohaven Pharmaceutical had 2 analyst reports since May 31, 2017 according to SRatingsIntel. The company was initiated on Wednesday, May 31 by Morgan Stanley. The company was initiated on Friday, December 15 by Canaccord Genuity.

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders. The company has market cap of $952.31 million. The Company’s advanced product candidate includes rimegepant, which is intended to initiate two Phase III clinical trials for the acute treatment of migraine; and trigriluzole, which is in a Phase II/III clinical trial used for the treatment of ataxias with an initial focus on spinocerebellar ataxia. It currently has negative earnings. The firm also develops BHV-3500 for the prevention of chronic and episodic migraine; BHV-0223 for the treatment of amyotrophic lateral sclerosis, a neurodegenerative disease that affects nerve cells in the brain and spinal cord; and BHV-5000 for the treatment of symptoms associated with Rett syndrome, such as breathing irregularities.

More notable recent Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) news were published by: Seekingalpha.com which released: “Biohaven Pharmaceuticals Seeks $125 Million IPO” on May 01, 2017, also Seekingalpha.com with their article: “Biohaven Pivots To Take A Shot At Migraine” published on July 27, 2017, Seekingalpha.com published: “Biohaven’s trigriluzole fails to beat placebo in Phase 2/3 study in …” on October 02, 2017. More interesting news about Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) were released by: Marketwatch.com and their article: “Biohaven Pharmaceutical raises $168 million in initial public offering” published on May 04, 2017 as well as Seekingalpha.com‘s news article titled: “Early-stage study underway for Biohaven’s trigriluzole” with publication date: October 30, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.